Bleomycin Sulfate

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 M2TYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:yd3Qx6oDVMUCwNEDPxG1? NYC4cZpMOjRiaNMg NUO5SI9wcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NVjmXmZyOjZyOEi3NVE>
POLK WT MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vCU2lEPTB;MUGuO-KBkcLz4pEJNU44yqEQvF2= NWH2Z3pFOjZyM{G0NFA>
POLK KO NXXJTpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;UWmlEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN NGnrWmQzPjB|MUSwNC=>
POLK CD MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwNUpihKnDueLCiUGuNFDDqM7:TR?= M{jCPVI3ODNzNECw
RLE/Abca3 M4\aVmZ2dmO2aX;uJGF{e2G7 MnLyNE41yqEQvF2= NEH6R5QyPDUEoHi= MV7pcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi MYGyOVc3ODV|OB?=
PMCs M2LpW2Z2dmO2aX;uJGF{e2G7 MnHzNE4y6oDVMtMg{txoN22u M373NFI1yqCq MkDQZ4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi NWDLW2FIOjV3OUW2OFI>
PMCs M{joWmZ2dmO2aX;uJGF{e2G7 MmXnNE4zyqEQvHevcYw> Mn;WNlTjiJN5MtMgbC=> NWWzTY5ycW6mdXPld{BqdmO{ZXHz[ZMhcW5idnnt[Y51cW5iYX7kJO6yNVOPQTDwdo91\Wmw NWr3NmNvOjV3OUW2OFI>
PMCs M1jCS2Z2dmO2aX;uJGF{e2G7 MljZNE4zyqEQvHevcYw> MYe3NkBp M2nzbYlv\HWlZYOg[IVkemWjc3XzJIlvKGO7dH;r[ZJifGmwLUigZY5lKEVvY3HkbIVzcW5icILveIVqdg>? NIfxbFEzPTV7NU[0Ni=>
PMCs NX7Rd4g2TnWwY4Tpc44hSXO|YYm= NXjIXGM4OC5{wrFOwIcwdWx? M1TGTVEzNzJ2L{S4JIg> M2Hxe4lv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= NVnIeYNSOjV3OUW2OFI>
IMR-32 NHrzS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3MlXjkJJzMkCgxtVoN22u MlS3NVLjkJJ2ODDo MnnlTWM2OD14MDFCuYcwdWxiYYSgeIhmKGWwZDDv[kAzPCCqcoOgc4YhcW6ldXLheIlwdg>? NU\hN3BCOjV3M{[zOFU>
HT1080 NWjQfZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f5elEh|ryP M4XqZlI1KGkEoB?= MoDRcIVi\HNidH:gZUBIOi:PIHTlcIF6 MYOyOVUyQDl4MR?=
HT1080 MXzGeY5kfGmxbjDBd5NigQ>? NX[4bnViOSEQvF2= MnjwNlQhcMLi NIPudVhqdmS3Y3XzJIEheG:2ZX70JIdtd2KjbDDEUmEh\GGvYXflJJJme3CxboPl MYiyOVUyQDl4MR?=
HDFn M4G1VGN6fG:2b4jpZ4l1gSCDc4PhfS=> M4DYZlczKGh? MYrJR|UxRTlwM{GlxsA> NXXnfVhuOjV{N{[3PVI>
THP-1 M2fUdWN6fG:2b4jpZ4l1gSCDc4PhfS=> NUfMTWJqPzJiaB?= MXTJR|UxRTRwN{el NH3pN4kzPTJ5Nke5Ni=>
HT-29 NFm2TJZEgXSxdH;4bYNqfHliQYPzZZk> NXjnfWF5PzJiaB?= MWXJR|UxRTFzLkS5KS=> NVLC[lhrOjV{N{[3PVI>
HCT116  NEHpb2tEgXSxdH;4bYNqfHliQYPzZZk> MofJO|IhcA>? NUf4VJhmUUN3ME2xNU4{PCV? MlzjNlUzPzZ5OUK=
A431 NVPzXFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xs[FUxNTJyMDDJWS=> NGrFc4Y1QOLCiXi= NYPB[pVXcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NY\iVGlMOjVzMEGyPVk>
T24 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLEOVAuOjByIFnV M3fndVQ56oDLaB?= MmGxbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3vm[VI2OTBzMkm5
AY-27  M3\ITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC1NE0zODBiSWW= M3K3[VQ56oDLaB?= NEDMTnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NUXEW4RQOjVzMEGyPVk>
A549 MnrZSpVv[3Srb36gRZN{[Xl? MVexJOK2\y:vTNMg M{e5S|AuPDhiaB?= NVzMbndEcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? NWHKb4lROjR7NkO2N|U>
MLE12 NWiySYF5TnWwY4Tpc44hSXO|YYm= MUGxJOK2\y:vTNMg MYewMVQ5KGh? NWnl[YlKcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? NEX5NGYzPDl4M{[zOS=>
Jurkat NFHkNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnQfFR2OjEkgJpOwI0> MoGyNlTjiImqwrC= MYThdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> MWmyOFkyPjh7Mx?=
HeLa  NH36N2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M322RmlEPTB;MUCuNuKh|ryP NGfV[JgzPDd|MkO5Oy=>
C18-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Z[GtMOC1zMECg{txO M{fEXolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NYLOVGd[OjR3N{G5PFI>
BMG-1  NGi1bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX1dno1OC96MNMg{txoN21? MmToN:KhcA>? MVXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MUWyN|kxPjd{Nh?=
A459 NVX0co9wSXCxcITvd4l{KEG|c3H5 MU[xNEBuXQ>? MX60PEBp NVvQfXBocW6mdXPld{BieG:ydH;zbZM> NFuxZnkzOzlyMke2Oi=>
MOCK MXjBdI9xfG:|aYOgRZN{[Xl? MX:xNEBuXQ>? NUPtV3VJPDhiaB?= NX\UcZBmcW6mdXPld{BieG:ydH;zbZM> MVqyN|kxOjd4Nh?=
MMP1 NEGwZ3dCeG:ydH;zbZMhSXO|YYm= MUGxNEBuXQ>? MWC0PEBp MlrqbY5lfWOnczDhdI9xfG:|aYO= NYHQU2NHOjN7MEK3OlY>
A549 M4LBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPjfGozODBizszN NHPxbm0zPCCqwrC= NVG1O|d7\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MY[yN|gxPTd7Mx?=
HCT-116 Mof6RZBweHSxc3nzJGF{e2G7 M1LUV|MwPy53L{G1JO69\y:vbB?= NX;XOXFmPDhiaB?= MlP5doVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> MorxNlM4ODh4Nki=
HeLa NHy3bZlCeG:ydH;zbZMhSXO|YYm= NYftOYhjOy95LkWvNVUh|rypL33s NHP1NnQ1QCCq NEDrdmhz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v M{\1ZVI{PzB6Nk[4
HCT116 M1fITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XubVAuOTByIN88[{9udA>? Mnr5OFghcA>? NUTEbYtOcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NWDMeGQ3OjN3MUiyNFE>
NCM460 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnrNE0yODBizsznM41t MU[0PEBp NHX5bpBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NGXsUIozOzVzOEKwNS=>
NT2  MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNWZVOOjRiaNMg M{PkdGxFPTB;NECw5qCKyrWpL33s MUWyN|M5PjR{MB?=
NT2  MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnviOFghcA>? MoXXUGQ2OD1zMECgxtVoN22u Mk[xNlM{QDZ2MkC=
NT2  NFH3R21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjIZVc4OiCq Ml6zUGQ2OD1{MPMAjeK2\y:vbB?= NH;yOJQzOzN6NkSyNC=>
NT2  M1y1V2Fxd3C2b4Ppd{BCe3OjeR?= M4nudlQxOOLCidM1[{9udA>? MYqyOEBpyqB? NYHVW|NFcW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi NVHaZnFYOjN|OE[0NlA>
NTera-2 M{C5bGZ2dmO2aX;uJGF{e2G7 MY[xNlAh|rypL33s NWjEbVZvPzJiaB?= M{jQcJNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NUfmT3BvOjJ6MkWzOVU>
NCCIT Mof2SpVv[3Srb36gRZN{[Xl? MWGxNlAh|rypL33s MYK3NkBp NYTPUI4ye2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> NW[zcWpCOjJ6MkWzOVU>
NTera-2 M3n6ZWZ2dmO2aX;uJGF{e2G7 MmrsNVIxKM7:Zz;tcC=> M1vNV|czKGh? NXLVNpJCe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ MWOyNlgzPTN3NR?=
NCCIT MWrGeY5kfGmxbjDBd5NigQ>? NIWyRmoyOjBizsznM41t M2rqWVczKGh? NX\nRphbe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ M{LJb|IzQDJ3M{W1
NCCIT M2HSbmZ2dmO2aX;uJGF{e2G7 NV34dWJ{OTJyIN88[{9udA>? NUfsOXN2PzJiaB?= M1XjSpNq\26rZnnjZY51dHliZHXjdoVie2W|IFfTTEBt\X[nbIO= NEPzW5kzOjh{NUO1OS=>
NTera-2 NF7NVFRHfW6ldHnvckBCe3OjeR?= MYKxNlAh|rypL33s MYK3NkBp MV7zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> MWmyNlgzPTN3NR?=
NCCIT NGfmTldHfW6ldHnvckBCe3OjeR?= NXnT[YxmOTJyIN88[{9udA>? NXizTnZXPzJiaB?= Mm[wd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MmjwNlI5OjV|NUW=
NTera-2 NVvFOGRDTnWwY4Tpc44hSXO|YYm= MonDNVIxKM7:Zz;tcC=> NX2xN4ZLPzJiaB?= NU[4XnlCe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MorQNlI5OjV|NUW=
NCCIT NFSyXVZHfW6ldHnvckBCe3OjeR?= MUOxNlAh|rypL33s MX:3NkBp NHP3VGd{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz M{P5UlIzQDJ3M{W1
MDA-MB-468 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjuNQKBmzJyMNMg{txoN22O NHS5SXgzPCCq M3zURolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFPlbI8zOjhzOUG5Oi=>
231-H2N NITFVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPjNQKBmzJyMNMg{txoN22O NEfaXoEzPCCq M3P2WolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M1OxTVIzQDF7MUm2
A549  MVjGeY5kfGmxbjDBd5NigQ>? MnLvNlAxNzRyMDFOwG0> NY\tcnZDemW|dXz0d{BqdiCjIHTvd4UuemW|cH;ud4l3\SCrbnPy[YF{\SCrbjDSU3M> NEWzT3QzOjd5M{[5Oy=>
A549  NVvwUYZCTnWwY4Tpc44hSXO|YYm= Mo\yNE01ODBizszN NVT0bWF{Oi12ODDo NYPlSpky[2G3c3XzJI1wemVibYTEUmEhfGijbjDuSG5CKGSjbXHn[S=> NIPEbXkzOjd5M{[5Oy=>
A549  Mo\ZSpVv[3Srb36gRZN{[Xl? M2myb|ExOCEQvF5CpC=> M2nneFDjiJN2ODDo NFP5T5hk[XW|ZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> MoTTNlI4PzN4OUe=
A549  NWfJUYZiTnWwY4Tpc44hSXO|YYm= NHf6OGIyODBizszNxsA> NX3XVVVtOOLCk{S4JIg> NGPMfllk[XW|ZYOgVGtFOSClbHXheoFo\Q>? M3O0[lIzPzd|Nkm3
A549  MYfGeY5kfGmxbjDBd5NigQ>? M1zHW|ExOCEQvF5CpC=> MUWw5qCUPDhiaB?= NUnEN5Bv[2G3c3XzJI1qfG:laH;u[JJq[WxibH;jZYxqgmG2aX;uJI9nKEKjeB?= NXL1Uo5xOjJ5N{O2PVc>
A549  NHizdYxHfW6ldHnvckBCe3OjeR?= NEfMd|gyODBizszNxsA> MV2w5qCUPDhiaB?= NGrNOYtl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ M1LLXlIzPzd|Nkm3
MCF-7/Her-18  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzOoExNjR{LUG3NFAh|rypL33M MUiyOEBp MYnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NH;y[okzOjZ{MUSwOC=>
MCF-7 NHnwV4hRTFRxUFPJJHRz\WG2bXXueC=> MlLzNE4zPSEQvHevcYwv MWSxMVQhcA>? NVzKRWtoe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MnLyNlI2QTF{OES=
MDA-MB-231 M1ToUnBFXC:SQ1mgWJJm[XSvZX70 NIPPUWwxNjJ3IN88[{9udC5? Mny3NU01KGh? NULIW5k3e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? NHPKTGozOjV7MUK4OC=>
MDA-MB-235  NGXFSIlRTFRxUFPJJHRz\WG2bXXueC=> NX\ie29IOC5{NTFOwIcwdWxw NIXXZnIyNTRiaB?= M4rmOpNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> M1;SNlIzPTlzMki0
MCF-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1roZVAuOiEQvHevcYwv MWGyOE81QCCq NUD4S25rTUN3ME2xMlIh|rypL33M M2fofFIzPTlzMki0
NCCIT  NYTIXJZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLMN45vOjEkgKOxOFDDqM7:Zz;tcC=> NVHlNWdbPzJiaB?= MoLQUGQ2OD1zMkFCpO69\y:vbNMg MnTNNlI2PjJzNkC=
NCCIT  M3z1UWZ2dmO2aX;uJGF{e2G7 NVj5WpRyPzJiaB?= MYjzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNiYXP0bZZqfHoEoB?= NGP3VoIzOjV4MkG2NC=>
NCCIT  M4HuUWZ2dmO2aX;uJGF{e2G7 Ml:2O|IhcA>? NHj3[nh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> NFv5d2MzOjV4MkG2NC=>
NCCIT  MVXGeY5kfGmxbjDBd5NigQ>? NGnhNXU4OiCq M{PLS5Nq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg MYWyNlU3OjF4MB?=
NCCIT  NWDmWG9UTnWwY4Tpc44hSXO|YYm= MoW2O|IhcA>? M1mwTZNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= MnjXNlI2PjJzNkC=
NCCIT  NEDjfllHfW6ldHnvckBCe3OjeR?= M4mwPVczKGh? MXjzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgRoNtNTJiY3;ueIVvfA>? MnXCNlI2PjJzNkC=
NCCIT  NF2zWmxHfW6ldHnvckBCe3OjeR?= NWL5V|I5PzJiaB?= NH3Y[ZN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhS3m2LXOgcIV3\Wx? M2TPU|IzPTZ{MU[w
HeLa MmW3SpVv[3Srb36gRZN{[Xl? Mn31N|AwPzBizsznM41t MkW4NlTDqGh? MonGbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> NInxWnAzOjR6N{mzOy=>
MCF-7  NHLYfoVHfW6ldHnvckBCe3OjeR?= MnvuN|AwPzBizsznM41t NVPIOnFzOjUEoHi= MmjNbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> NUK5R4dROjJ2OEe5N|c>
HeLa M2rUcGN6fG:2b4jpZ4l1gSCDc4PhfS=> MmP0N|AwPzBizsznM41t NH7OS3QzPMLiaB?= NVLOTlRocW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt M13nOFIzPDh5OUO3
MCF-7  NX;hSIR3S3m2b4TvfIlkcXS7IFHzd4F6 M33helMxNzdyIN88[{9udA>? MnPPNlTDqGh? M1fqXIlv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= NVHlSVNpOjJ2OEe5N|c>
NT2 NUjPPG55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3NVAxNTZyMNMg{txoN22u M2PIdVI1KGh? NGPOOoZKSzVyPUSwNEDDvWdxbXy= MWCyNlQ3QTl3Mh?=
NT2 M1:wNGZ2dmO2aX;uJGF{e2G7 NFzUTpQ1ODEEoN88[{9udA>? MmjaNlQhcA>? NX3j[INNe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi M3:wN|IzPDZ7OUWy
NT2 Mn7FSpVv[3Srb36gRZN{[Xl? NXzJbnJCPDBywrFOwIcwdWx? M{O3eVI1KGh? NGKzUZB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= NUTRSm5ZOjJ2Nkm5OVI>
NT2 NFvYSVhHfW6ldHnvckBCe3OjeR?= MnXZOFAxyqEQvHevcYw> MkjjNlQhcA>? MY\zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= NWHpV4NLOjJ2Nkm5OVI>
CHO M1LWNmZ2dmO2aX;uJGF{e2G7 MlX1Nk42yqEQvHevcYw> M1fRXlE5KGhxNjDk NGTiZ4dqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= MmfsNlIzOzBzOUW=
Jurkat MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUZ|AuOTBywrFOwIcwdWx? MnnoNlQhcA>? NHv4flVienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? MV6yNlIzOzN|Mh?=
Jurkat MWnGeY5kfGmxbjDBd5NigQ>? NUflN4JDOzEEoN88[{9udA>? MYWyOEBp MXHpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz MorGNlIzOjN|M{K=
Jurkat MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fORlAuOTBywrFOwIcwdWx? NI\nc44zPCCq MmrRbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? NIixOJIzOjJ{M{OzNi=>
Jurkat NHXQcIVHfW6ldHnvckBCe3OjeR?= M3TX[VMxyqEQvHevcYw> NEexdHMzPCCq NIH0SYNqdmO{ZXHz[ZMhfGinIHXm[oVkfCCxZjDwfYNvcWSrb37lJI9vKHCqb4PwbI9zgWyjdHnvckBt\X[nbIOgc4YhcGm|dH;u[UBJOkFwWB?= NYnk[XM{OjJ{MkOzN|I>
U2OS EGFPnls M3u1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwOVgxNTMEoN88[{9udA>? MkTXNlQhcA>? MoWzbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mke0NlE5OTFyMEe=
U2OS KuEnls NX[3VmdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG3dHNyOC1{wrFOwIcwdWx? MUGyOEBp M4rVSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> Mnn5NlE5OTFyMEe=
MCF-7 NWPEZ2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TtSlAuPDByIN88US=> MX[3NkBp M2O2TmxEPTB;MUWxMljDqM7:TR?= M{WzRVIyPzB|Mkmx
MCF-7/Adr  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5bFAuPDByIN88US=> NUHrPIJEPzJiaB?= MX;MR|UxRTV6LkZCpO69VcLi MlK0NlE4ODN{OUG=
WI-38 NYDJOFJ4TnWwY4Tpc44hSXO|YYm= MkTXNE81OC96MPMAje69\y:vbNMg MUSzJIg> NIH5PZhqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MYWyNVU6QTZzMh?=
hBMSC M2rsPWZ2dmO2aX;uJGF{e2G7 MVWwM|QxNzhy4pEJ{txoN22uwrC= MXizJIg> MlK4bY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NFPhVGIzOTV7OU[xNi=>
NCI-H23 M{LTd2Z2dmO2aX;uJGF{e2G7 MkfyNE81OC96MPMAje69\y:vbNMg NFfMfI8{KGh? Ml\GbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MlX6NlE2QTl4MUK=
A-549 NFzoflZHfW6ldHnvckBCe3OjeR?= MoDTNE81OC96MPMAje69\y:vbNMg MWWzJIg> MYjpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg MorjNlE2QTl4MUK=
PBL  MWLGeY5kfGmxbjDBd5NigQ>? NXr5ZmRXOC92MD:4NQKBkc7:Zz;tcOKh M{i5OlMhcA>? M3;jbYlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NEDoeoUzOTV7OU[xNi=>
pol β −/− NU\nSIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGwUIkxNjJ3LUKwNOKh|rypL33s MVSyOOKhcA>? NF3VT2ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NULNO414OjF{NUG5OFQ>
pol β +/+ M1HXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi3Um94OC5{NT2yNFDDqM7:Zz;tcC=> MYiyOOKhcA>? NF75[Ydl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NVrId5BOOjF{NUG5OFQ>
pol β −/− MmTTSpVv[3Srb36gRZN{[Xl? NIXJfG8xNTJwNTFOwIcwdWx? MVuyJIg> MVnjZZV{\XNiRF7BJIRidWGpZR?= MXSyNVI2OTl2NB?=
pol β +/+ NWrROlVjTnWwY4Tpc44hSXO|YYm= MkXYNE0zNjVizsznM41t MnL1NkBp MoPvZ4F2e2W|IFTORUBl[W2jZ3W= NInuVpUzOTJ3MUm0OC=>
pol β −/− NY\TOXc3TnWwY4Tpc44hSXO|YYm= M1PjUlAuPSEQvHevcYw> MmG5OFghcA>? NWDHR2Zx[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M131[lIyOjVzOUS0
pol β +/+ NGro[JZHfW6ldHnvckBCe3OjeR?= NWWzboh1OC13IN88[{9udA>? NVLZW|MyPDhiaB?= Mlz5Z4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MV2yNVI2OTl2NB?=
TK6  M{XWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnwRlkzPS1zNUCg{txoN22u NFryfow6PiCq NGPT[2RqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M4PIS|IyODhzNEi3
TK6  sLUC+Apn1 M{\rSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuyTIUzPS1zNUCg{txoN22u M17MfFk3KGh? NGqyenlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{HWd|IyODhzNEi3
TK6 sAPE1+Apn1 NIHyPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TrfFI2NTF3MDFOwIcwdWx? M{K4c|k3KGh? NWXpdFBje2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NF;5UoczOTB6MUS4Oy=>
HCT116 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\WNlI2NTF3MDFOwIcwdWx? NF3KUFY6PiCq M{\UfolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M2C2[VIyODhzNEi3
HCT116 sLUC+Apn1 M3jSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe1OJNFOjVvMUWwJO69\y:vbB?= MlHaPVYhcA>? NXvzW4xmcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4jOcVIyODhzNEi3
HCT116 sAPE1+Apn1 M1qxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;GN|BGOjVvMUWwJO69\y:vbB?= NGTsXHY6PiCq NULh[WxFe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NVfUUpd5OjFyOEG0PFc>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

+ 展開
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD-1 mice
  • 製剤: Saline
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
Saline
いい結果が出るために、混じった後、直ちに使うと推めます。
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
保管
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • 回答:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • 問題2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

Related Antibodies

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID